Accès ouvert · CC BY

Author comment: Clinical application of circulating cell-free lymphoma DNA for fast and precise diagnosis of Burkitt lymphoma: Precision Medicine for Sub Saharan Africa — R0/PR1

Rapport d'évaluation 2022 Sciences de la vie et biotechnologies › Biotechnologies (OCDE 2.9) Anglais

Résumé

Burkitt lymphoma (BL) has a cure rate of around 95% when treated with chemo-immunotherapy that is standard of care in high-income countries (Minard-Colin et al., 2020, New England Journal of Medicine 382, 2207–2219), but currently, more than 50% of children and young adults with endemic BL (Epstein Barr virus driven BL) in sub-Saharan Africa (SSA) do not survive. Treatment for BL is largely free of charge, but there is limited access to reliable diagnostic services leading to significant delays and misdiagnoses. Innovations in histopathology such as whole slide imaging and the use of novel diagnostic approaches, in particular using circulating cell-free viral and/or lymphoma DNA (liquid biopsy), could increase access to timely and reliable diagnosis and improve outcomes in SSA.

Citer ce document

Chamba, C. (2022). Author comment: Clinical application of circulating cell-free lymphoma DNA for fast and precise diagnosis of Burkitt lymphoma: Precision Medicine for Sub Saharan Africa — R0/PR1. https://doi.org/10.1017/pcm.2023.1.pr1

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 10/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Auteur(s)

Statistiques

Consultations (hors robots) : 13

Téléchargements (hors robots) : 0

Méthode de comptage